Notícias Amneal Pharmaceuticals Inc - AMRX | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Amneal Pharmaceuticals Inc (AMRX)
Amneal Pharmaceuticals Inc (AMRX) Notícias

Amneal Pharmaceuticals Inc (AMRX)

8,72

-0,01

( -0,11% )

Atualizado: 11:33:09

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amneal to Participate at Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Amneal Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições